BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug

By Investor's Business Daily   |   1 year ago
BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug

BridgeBio received early approval to launch its drug, acoramidis, for treating transthyretin amyloid cardiomyopathy. The drug, to be sold as Attruby, will compete with Pfizer's Vyndaqel.

Read More

Did you find this insightful?